ImmuCell Corporation Equity Classified Written Call Option Modification Decrease In Net Income Loss To Common Shareholder Amount
ImmuCell Corporation (ICCC) reported Equity Classified Written Call Option Modification Decrease In Net Income Loss To Common Shareholder Amount of $222.38 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-11-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:EquityClassifiedWrittenCallOptionModificationDecreaseInNetIncomeLossToCommonShareholderAmount · last filed 2022-11-21
- ImmuCell Corporation equity classified written call option modification decrease in net income loss to common shareholder amount for the quarter ending 2022-06-30 was $0.00.
- ImmuCell Corporation equity classified written call option modification decrease in net income loss to common shareholder amount for the quarter ending 2022-03-31 was $222.38K.
| Period end | Equity Classified Written Call Option Modification Decrease In Net Income Loss To Common Shareholder Amount 3 month | Equity Classified Written Call Option Modification Decrease In Net Income Loss To Common Shareholder Amount 6 month |
|---|---|---|
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-21 | $222.38K 10-Q · filed 2022-11-21 |
| 2022-03-31 | $222.38K 10-Q · filed 2022-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |